Study summary

A PD-L1 and VEGF bispecific antibody shrank tumors in about three in four patients

Pumitamig early trial · 42 people, phase 1b/2 · Published November 2026, Lancet Oncology

73.8%of tumors shrank

What was tested

Pumitamig, an antibody blocking both PD-L1 and VEGF, with nab-paclitaxel as first treatment for advanced TNBC. Single-arm trial in China, no comparison group.

What they found

What it means

Now in the phase 3 ROSETTA Breast-01 trial run by BioNTech.

Lancet Oncol, via PubMed ↗ Trial record NCT05918133 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.